News | Atrial Fibrillation | September 01, 2017

CASTLE-AF Study Results Indicate Catheter Ablation of Atrial Fibrillation as First-Line Treatment for Heart Failure Patients

Presentation at ESC, catheter ablation shows significant reduction in mortality and heart failure events with compared to pharmacological therapy
 

CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause mortality and hospitalization for worsening heart failure, when heart failure patients with atrial fibrillation (AF) are treated with catheter ablation, compared to pharmacological therapy recommended by current guidelines. The outcomes were presented at a Late-Breaking Clinical Trials Hot Line session during the European Society of Cardiology’s ESC Congress 2017 in Barcelona.

The study was led by Nassir Marrouche, M.D., University of Utah, Salt Lake City, US and Dr. Johannes Brachmann, Coburg Clinic, Germany and sponsored by Biotronik. CASTLE-AF (Catheter Ablation versus Conventional Treatment in Patients with Left Ventricular Dysfunction and Atrial Fibrillation) is the world’s largest randomized clinical study on the efficacy of catheter ablation for AF in ICD or CRT-D patients suffering from heart failure. The study enrolled 398 patients in 33 sites across Europe, Australia and the US between 2008 and 2016. It is the first catheter ablation study to measure the primary composite outcome of mortality and morbidity with a mean follow-up of more than three years.

“CASTLE-AF is currently the only existing study that measures a hard primary outcome in patients who have received catheter ablation or conventional therapy for AF,” Marrouche said. “The results of this trial underscore the importance of catheter ablation as a mode of treatment, indicating that the procedure should be performed as early as possible and as a first-line therapy in this group of patients.”

In addition to achieving a significant reduction in the primary composite outcome, the study showed that AF ablation significantly reduced both of the components of the primary outcome, with a 47 percent reduction in mortality and a 44 percent decrease in hospitalization for worsening heart failure.

“There has been a general lack of consensus within the scientific community on the most appropriate way to manage AF in heart failure patients,” said Brachmann. “The indicative results from CASTLE-AF could pave the way for wider adoption of catheter ablation and may prompt changes in current guidelines for treatment. This could have a considerable impact on heart failure patients with coexisting AF.”

Read the article “Trial Targets Alternative A-Fib, Congestive Heart Failure Therapy.”

For more information www.castle-af.org

Related Content

Boston Scientific to Acquire Cryterion Medical Inc.
News | Ablation Systems | July 13, 2018
Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held...
Treating AFib With Ablation Reduces Mortality and Stroke
News | Ablation Systems | July 05, 2018
Using catheter-based ablation instead of medications alone reduces the risks of death and stroke in patients with the...
LuxCath Showcases OmniView Light-Guided Ablation Catheter at HRS 2018
News | Ablation Systems | May 22, 2018
LuxCath LLC showcased the next generation of its proprietary OmniView light-guided catheter ablation system at the 2018...
The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously.  #HRS2018

The Kardium Globe combined mapping and ablation catheter. The device has a distal multi-electrode array consisting of 16 ribs with 122 gold-plated electrodes. Ablation can be done with up to 24 electrodes simultaneously. 

News | Ablation Systems | May 21, 2018
May 21, 2018 — Complete pulmonary vein isolation (PVI) was achieved in more than 99 percent of patients in a first-in
CardioFocus Announces Successful Live Case Featuring HeartLight X3 System
News | Ablation Systems | May 17, 2018
Medical device manufacturer CardioFocus Inc. announced a successful live case featuring its HeartLight X3 System during...
Imricor MRI-Guided Cardiac Ablation Study Results to Be Presented at HRS 2018
News | Ablation Systems | May 10, 2018
Results from the clinical study to evaluate Imricor’s Vision-MR Ablation Catheter for the treatment of atrial flutter...
Biosense Webster Launches Carto Vizigo Bi-Directional Guidance Sheath
Technology | Ablation Systems | May 08, 2018
Biosense Webster Inc. announced its Carto Vizigo Bi-directional Guiding Sheath is now available in the United States....
Stereotaxis and Acutus Medical Announce Strategic Collaboration
News | Ablation Systems | May 04, 2018
Stereotaxis and Acutus Medical announced a strategic collaboration to integrate the Stereotaxis Niobe Magnetic...
Medtronic Cryoballoon Shows Positive Results for Patients With Persistent Atrial Fibrillation
News | Ablation Systems | April 12, 2018
Medtronic plc announced one-year results from the CRYO4PERSISTENT AF study of ablation with the Arctic Front Advance...
Boston Scientific Acquires Securus Medical Group Inc.
News | Ablation Systems | April 04, 2018
Boston Scientific Corp. announced the acquisition of Securus Medical Group Inc., a privately-held company that has...
Overlay Init